Report ID: 10076462 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global diabetic neuropathy market to reach USD 5.8 billion by 2025.
Global diabetic neuropathy market is valued approximately USD 3.8 billion in 2017 and is anticipated to grow with a healthy growth rate of more than 5.4 % over the forecast period 2018-2025. Key trends in the market is advent of new therapeutics for treatment of neuropathy and favorable reimbursement scenario which is expected to foster the growth of the diabetic neuropathy market. For instance: In 2016 as per the University of Cambridge, researchers have led to the development of a new approach to treatment of neuropathic pain. Further, the project focuses on a novel way of indirectly modulating the effect of the TRPV1, a significant initiator of the sensation of pain. Additionally, the team worked to show the effectiveness of using certain peptides to interface with the function of TRPV1 with an aim to eliminate neuropathic pain. As a result, healthcare institutions would be capable to deliver new therapeutics for treatment of neuropathy.
Key driving factors for the diabetic neuropathy market are rising prevalence of diabetes coupled with the changing lifestyles that results in to unhealthy dietary habits and patterns. According the Health Metrics - American Heart Association, in 2010 the prevalence of diabetes for adults was recorded to be 6.4% globally. This is expected to increase and reach up to 7.7% by the end of 2030, across the globe. Similarly, as per the MRC United Kingdom 2015, the estimated diabetes prevalence for adults between age group of 20-79 worldwide was around 387 million in 2014 which is estimated to reach around 592 million people by 2023. As a result, people suffering from diabetes are prone to nerve damages which are expected to boost the growth of the diabetic neuropathy market during 2018-2025. Furthermore, rise in demand for better neuropathy drugs offer lucrative growth prospects for the diabetic neuropathy market across the globe. However, high cost associated with diabetic neuropathy along with the side effects of the drugs are expected to hinder the growth of the market during the forecast period.
On the basis of segmentation, the diabetic neuropathy market is segmented into disorder type, treatment and distribution channel. The disorder type segment of global Diabetic neuropathy market is classified into autonomic Neuropathy, peripheral neuropathy, proximal neuropathy and focal neuropathy of which proximal neuropathy dominates the market as it is the most commonly found disorder in type 2 diabetes. On the basis of treatment segment, the market is classified into drugs, physiotherapy, radiotherapy and others. The distribution channel segment is classified into clinics, hospitals and pharmacy.
The regional analysis of diabetic neuropathy market is considered for the key regions such as North America, Europe, Asia Pacific, Latin America and ROW. North America holds the leading position in diabetic neuropathy market owing to the increase in prevalence of diabetes, improved healthcare infrastructure along with the rise in research and development activities. Whereas, Asia-Pacific is expected to emerge as the fastest growing region in terms of market share. The growth of Asia-Pacific is witnessed owing to increase R&D activities for drug discovery along with increasing aging population. Also, improving healthcare infrastructure and services in rural areas is also expected to supplement the growth of Asia-Pacific over the forecast period.
The leading market players include-
 Pfizer Inc.
 Janssen Pharmaceuticals, Inc.
 Eli Lilly and Company
 Cephalon, Inc.
 ACTAVIS
 GlaxoSmithKline
 MEDA Pharma GmbH & Co. KG
 NeuroMetrix, Inc
 Abbott Laboratories
 Lupin Limited
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Disorder Type
 Autonomic Neuropathy
 Peripheral Neuropathy
 Proximal Neuropathy
 Focal Neuropathy
By Treatment:
 Drugs
 Physiotherapy
 Radiotherapy
 Others
By Distribution Channel:
 Clinics
 Hospitals
 Pharmacy
By Regions:
 North America
o U.S.
o Canada
 Europe
o UK
o Germany
o ROE
 Asia Pacific
o China
o India
o Japan
o ROAPEC
 LAMEA
o Brazil
o Mexico
 ROW
o Middle East & Africa
Furthermore, years considered for the study are as follows:
Historical year – 2015, 2016
Base year – 2017
Forecast period – 2018 to 2025
Target Audience of the Global Diabetic neuropathy Market in Market Study:
 Key Consulting Companies & Advisors
 Large, medium-sized, and small enterprises
 Venture capitalists
 Value-Added Resellers (VARs)
 Third-party knowledge providers
 Investment bankers
 Investors
呁
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10076462 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
